 based in Canada, for $925 million.){kind=link}
Agilent Technologies has announced its definitive agreement to acquire BIOVECTRA, a prominent contract development and manufacturing organization (CDMO) based in Canada, for $925 million. BIOVECTRA specializes in producing biologics, highly potent active pharmaceutical ingredients (HPAPIs), and other molecules for targeted therapeutics.
The acquisition aims to enhance Agilent’s CDMO capabilities in oligonucleotides and CRISPR therapeutics, focusing on three key areas:
- Expanded Service Portfolio: BIOVECTRA provides sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle (LNP) formulation.
- Growth in Emerging Segments: Expertise in antibody drug conjugates (ADCs), HPAPIs, and GLP-1 will bolster Agilent’s offerings in rapidly growing markets.
- Enhanced Gene Editing Support: Combining BIOVECTRA’s biologics capabilities with Agilent’s expertise in gRNA will offer customers comprehensive gene-editing solutions.
Both companies operate facilities adhering to current Good Manufacturing Practices (cGMP), ensuring high standards in manufacturing, processing, and packaging of active pharmaceutical ingredients.
Agilent President and CEO Padraig McDonnell commented, “We look forward to welcoming BIOVECTRA to Agilent. The company has an outstanding record of innovation, and its employees share our commitment to providing integrated biopharma solutions that continuously deliver more value to customers. BIOVECTRA’s manufacturing capabilities further expand Agilent’s end-to-end biopharma offerings into new growth vectors, including workflows that seamlessly integrate analytical instrumentation, consumables, and a wide range of lab services.”
BIOVECTRA supports early-stage clinical development through to large-scale commercial manufacturing, serving biotech and pharmaceutical companies in North America and Europe. Oliver Technow, CEO of BIOVECTRA, expressed enthusiasm about the acquisition, stating, “BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers aligns with ours. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers.”
The acquisition, subject to customary closing conditions and regulatory approvals, is expected to be completed before 2025. Upon completion, BIOVECTRA will become part of the Agilent Diagnostics and Genomics Group.